Country: Malta
Language: English
Source: Medicines Authority
HUMAN VON, WILLEBRAND FACTOR, HUMAN COAGULATION, FACTOR XIII
Octapharma (IP) SPRL Alle de la Recherche 65, 1070 (Anderlecht), Belgium
B02BD06
HUMAN VON WILLEBRAND FACTOR 1000 IU HUMAN COAGULATION FACTOR VIII 1000 IU
POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
HUMAN VON WILLEBRAND FACTOR 1000 IU HUMAN COAGULATION FACTOR VIII 1000 IU
POM
ANTIHEMORRHAGICS
Authorised
2018-01-10
Page 1 of 11 PACKAGE LEAFLET: INFORMATION FOR THE USER WILATE 500, 500 IU VWF/500 IU FVIII, powder and solvent for solution for injection WILATE 1000 , 1000 IU VWF/1000 IU FVIII, powder and solvent for solution for injection Human von Willebrand factor/human coagulation factor VIII READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Please keep this leaflet. You may need to read it again. • If you have further questions, ask your doctor or your pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Wilate is and what it is used for 2. What you need to know before you use Wilate 3. How to use Wilate 4. Possible side effects 5. How to store Wilate 6. Contents of the pack and other information 1. WHAT WILATE IS AND WHAT IT IS USED FOR Wilate belongs to the pharmacotherapeutic group of medicines called clotting factors and contains human von Willebrand factor (VWF) and human blood coagulation factor VIII. Together these two proteins are involved in blood clotting. Von Willebrand disease Wilate is used to treat and prevent bleeding in patients with von Willebrand disease (VWD), which in fact is a family of related diseases. VWD is a disturbance of blood coagulation where bleeding can go on for longer than expected. This is either due to a lack of VWF in the blood or due to VWF that does not work the way it should. Haemophilia A Wilate is used to treat and prevent bleeding in patients with haemophilia A. This is a condition in which bleeding can go on for longer than expected. It is due to an inborn lack of factor VIII in the blood. Page 2 of 11 2. WHAT YOU NEED TO KNOW BEFORE YOU USE WILATE DO NOT USE WILATE_ _ • if you are allergic (hypersensitive) to Read the complete document
Page _ _ 1/16 _ _ SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT WILATE 500, 500 IU VWF/500 IU FVIII, powder and solvent for solution for injection WILATE 1000, 1000 IU VWF/1000 IU FVIII, powder and solvent for solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Wilate is presented as a powder and solvent for solution for injection. Each vial contains nominally 500 IU/1000 IU human von Willebrand factor (VWF ) and human coagulation factor VIII (FVIII). The product contains approximately 100 IU/ml human von Willebrand factor when reconstituted with 5 ml/10 ml Water for Injections with 0.1 % Polysorbate 80. The specific activity of Wilate is 67 IU VWF:RCo/mg protein. The VWF potency (IU) is measured according to ristocetin cofactor activity (VWF:RCo) compared to the International Standard for von Willebrand Factor Concentrate (WHO). The product contains approximately 100 IU/ml human coagulation factor VIII when reconstituted with 5 ml/10 ml Water for Injections with 0.1% Polysorbate 80. The potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The specific activity of Wilate is 67 IU FVIII:C/mg protein. Produced from the plasma of human donors. Excipient(s) with known effect: Wilate 500: 11.7 mg sodium per ml reconstituted solution (58.7 mg sodium per vial). Wilate 1000: 11.7 mg sodium per ml reconstituted solution (117.3 mg sodium per vial). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for solution for injection. Freeze-dried powder: white or pale yellow powder or crumbly solid. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Von Willebrand disease (VWD) Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated. Haemophilia A Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Page _ _ 2/16 _ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Read the complete document